| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 41899 |
Unlisted procedure, dentoalveolar structures |
685 |
640 |
$1.92M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,813 |
5,911 |
$901K |
| 36415 |
Collection of venous blood by venipuncture |
18,570 |
15,341 |
$381K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,684 |
2,271 |
$366K |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
805 |
674 |
$357K |
| A0425 |
Ground mileage, per statute mile |
1,373 |
1,066 |
$322K |
| 80053 |
Comprehensive metabolic panel |
4,555 |
4,169 |
$203K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
813 |
711 |
$178K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,509 |
2,412 |
$173K |
| A0080 |
Non-emergency transportation, per mile - vehicle provided by volunteer (individual or organization), with no vested interest |
4,035 |
665 |
$153K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,544 |
4,161 |
$110K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
2,183 |
1,804 |
$100K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,819 |
1,618 |
$91K |
| A0100 |
Non-emergency transportation; taxi |
4,410 |
759 |
$80K |
| S0215 |
Non-emergency transportation; mileage, per mile |
2,014 |
552 |
$62K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,687 |
1,651 |
$52K |
| 00170 |
Anesthesia for intraoral procedures, including biopsy |
232 |
212 |
$46K |
| 85027 |
|
1,767 |
1,590 |
$38K |
| 64483 |
|
42 |
25 |
$36K |
| S0209 |
Wheelchair van, mileage, per mile |
835 |
231 |
$34K |
| J3490 |
Unclassified drugs |
1,732 |
920 |
$31K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,426 |
1,981 |
$29K |
| T2003 |
Non-emergency transportation; encounter/trip |
1,920 |
525 |
$26K |
| 86140 |
|
1,139 |
1,067 |
$24K |
| J2401 |
Injection, chloroprocaine hydrochloride, per 1 mg |
734 |
478 |
$21K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
66 |
65 |
$17K |
| A0130 |
Non-emergency transportation: wheelchair van |
875 |
243 |
$17K |
| J2400 |
Injection, chloroprocaine hydrochloride, per 30 ml |
396 |
346 |
$14K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
457 |
417 |
$14K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
154 |
50 |
$14K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
174 |
63 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
227 |
82 |
$13K |
| D1110 |
Prophylaxis - adult |
295 |
282 |
$12K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
316 |
277 |
$11K |
| 84443 |
Thyroid stimulating hormone (TSH) |
375 |
357 |
$10K |
| J2704 |
Injection, propofol, 10 mg |
274 |
169 |
$9K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
276 |
252 |
$9K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
134 |
53 |
$9K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
377 |
319 |
$8K |
| D1206 |
Topical application of fluoride varnish |
336 |
322 |
$7K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
149 |
139 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
190 |
176 |
$7K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
314 |
193 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
285 |
264 |
$6K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
57 |
54 |
$6K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
127 |
118 |
$6K |
| D9420 |
|
470 |
449 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
87 |
81 |
$5K |
| 87480 |
|
422 |
397 |
$5K |
| 87510 |
|
422 |
397 |
$5K |
| D0140 |
Limited oral evaluation - problem focused |
279 |
274 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
184 |
177 |
$5K |
| 81001 |
|
754 |
710 |
$5K |
| 87660 |
|
422 |
397 |
$5K |
| 84439 |
|
170 |
163 |
$4K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
102 |
78 |
$4K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
13 |
13 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
194 |
188 |
$3K |
| D1330 |
|
307 |
292 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
134 |
132 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
126 |
123 |
$3K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
45 |
19 |
$3K |
| 83655 |
|
99 |
97 |
$3K |
| 85652 |
|
158 |
148 |
$3K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
12 |
12 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
27 |
27 |
$3K |
| 83930 |
|
65 |
62 |
$2K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
43 |
41 |
$2K |
| 82728 |
|
39 |
38 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
84 |
60 |
$2K |
| 86850 |
|
84 |
40 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
43 |
41 |
$2K |
| 73630 |
|
16 |
12 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
56 |
50 |
$2K |
| 81003 |
|
145 |
130 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
40 |
38 |
$2K |
| 85018 |
|
73 |
72 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
41 |
38 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
41 |
38 |
$1K |
| 87088 |
|
40 |
39 |
$1K |
| 80061 |
Lipid panel |
45 |
44 |
$1K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
56 |
40 |
$1K |
| D2391 |
Resin-based composite - one surface, posterior, primary or permanent |
31 |
13 |
$1K |
| 73620 |
|
15 |
12 |
$1K |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
27 |
25 |
$948.79 |
| D0120 |
Periodic oral evaluation - established patient |
41 |
37 |
$793.28 |
| 87081 |
|
29 |
27 |
$774.58 |
| 80076 |
|
12 |
12 |
$583.56 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
17 |
13 |
$552.15 |
| 85651 |
|
28 |
28 |
$534.36 |
| 87186 |
|
17 |
17 |
$476.61 |
| 81025 |
|
18 |
17 |
$450.00 |
| 90682 |
|
24 |
24 |
$438.33 |
| 83540 |
|
12 |
12 |
$290.30 |
| D9920 |
|
389 |
340 |
$108.34 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
16 |
16 |
$31.68 |
| A9270 |
Non-covered item or service |
46 |
12 |
$12.50 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
16 |
16 |
$0.37 |
| 99188 |
|
12 |
12 |
$0.01 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
27 |
27 |
$0.00 |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
12 |
12 |
$0.00 |
| 90461 |
|
12 |
12 |
$0.00 |
| 96127 |
|
27 |
27 |
$0.00 |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
46 |
46 |
$0.00 |
| 90834 |
Psychotherapy, 45 minutes with patient |
26 |
24 |
$0.00 |
| 90686 |
|
16 |
16 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
18 |
18 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
76 |
73 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
171 |
144 |
$0.00 |